Programme

Accelerating the TB vaccine pipeline – towards Horizon Europe

27 January – 29 January 2020

Hotel Eurotel Victoria
Les Diablerets
Switzerland
Monday 27 January 2020
(Eurotel Victoria)

12.30 – 14.00  Buffet lunch (restaurant Eurotel)

15.00 – 18.00  -  TBVI R&D partner meetings

15.00 – 16.30  -  From TBVAC2020 to Horizon Europe
    -  WP 5 meeting – Tom Ottenhoff (LUMC) - room Isenau

16.30 – 17.00  Break

17.00 – 18.30  -  R&I group - room Diablerets  (Only for members of the R&I group and invited guests)

19.30  Dinner  (Restaurant Eurotel)
Tuesday 28 January 2020
(Maison des Congrès)

08.15 – 08.30 Welcome and introduction (Nick Drager, TBVI, the Netherlands)

08.30 – 10.00 **Progress in TB vaccine clinical product development**
(Chair: Paul Henri Lambert, TBVI, the Netherlands)

08.30 – 08.45 M72 - (Francois Roman, GSK, Belgium)
08.45 – 09.00 VPM1002 – “A pivotal multicenter phase III clinical trial” - (Sina Brueckner, VPM, Germany)
09.00 – 09.15 MTBVAC - “clinical development towards a new TB vaccine” - (Ingrid Murillo, BioFabri, Spain)
09.15 – 09.30 H56 – “Prevention of recurrence of TB: a phase II double-blind, randomised placebo-controlled trial” - (Alvaro Borges, SSI, Denmark)
09.30 – 09.45 RUTI - “Update on RUTI clinical development” - (Père-Joan Cardona, Archivel, Spain)
09.45 – 10.00 ID93 - (Rhea Coler, IDRI, United States)

10.00 – 10.30 **Coffee break**

10.30 – 12.30 **Rational selection and progression of TB vaccine candidates**
(Chair: Gerald Voss, TBVI, the Netherlands)

10.30 – 10.50 TB Vaccine Development Pathway - (Georges Thiry and Danielle Roordink, TBVI, Netherlands)
10.50 – 11.10 Preclinical candidate selection in TBVAC2020 - (Ann Rawkins, PHE, United Kingdom)
11.10 – 11.30 Portfolio assessment process - (Brij Patel, TBVI, the Netherlands)
11.30 – 12.30 Pathways to impact - (Panel Johan Vekemans, WHO, Switzerland; Frank Cobelens, AIGHD, the Netherlands; Richard White, LSHTM, United Kingdom; René Coppens, TBVI)

12.30 – 13.30 **Lunch** (Restaurant Eurotel)
Tuesday 28 January 2020 - afternoon

(Maison des Congrès)

14.00 – 18.00  **Current considerations in TB vaccine development**  
(Moderated workshop chairs: Beatrice de Vos. TBVI, the Netherlands; Hazel Dockrell, LSHTM, United Kingdom)

14.00 – 15.00 Emerging immune correlates and biomarkers  
*(Panel: Tom Ottenhoff, LUMC, the Netherlands; Babak Javid, TUSM, China; Hazel Dockrell, LSHTM, United Kingdom; Amita Gupta, RePORT, United States)*

15.00– 16.00 Clinical development, experimental medicine and novel clinical trial designs  
*(Panel: Ann Ginsberg, BMGF, United States; Michelle Tameris, SATVI, South Africa; Dereck Tait, IAVI, United States; Bernard Fritzell, TBVI, the Netherlands; Helen McShane, UOXF, United Kingdom)*

16.00-16.30  *Coffee break*

16.30– 17.30 Whole cell vaccines  
*(Panel: Roland Brosch, IP, France; Olivier Neyrolles, CNRS, France; Sally Sharpe, PHE United Kingdom; Pere-Joan Cardona, IGTP, Spain; Daria Bottai, UNIPI, Italy)*

17.30 – 18.00 Discussion of workshop conclusions (session chairs)

19.00  *Dinner (restaurant Eurotel)*
**Wednesday 29 January 2020**

(Maison des Congrès)

08.30 – 12.00 **Discovery and translation into lead candidates**
(Chair: Willem Hanekom, AHRI, South Africa)

**Immunological mechanisms of protection**

08.30 – 08.45 Steffen Stenger, (UKU, Germany)
08.45 – 09.00 “Functional assays contribute mechanistic insights into mycobacterial growth control” - Simone Joosten, (LUMC, the Netherlands)
09.00 – 09.15 “A Next Generation Subunit Vaccine for Co-administration with BCG” - Joshua Woodworth, (SSI, Denmark)
09.15 – 09.30 Rajko Reljic, (SGUL, United Kingdom)

**Progress in preclinical models**

09.30 – 09.45 “Animal models in TB vaccine development: report of a NIH/BMGF meeting in September 2019” - Willem Hanekom, (AHRI, South Africa)
09.45 – 10.00 “Distinctive adaptive and trained innate responses after protective mucosal BCG or MTBVAC vaccination in NHP” - Frank Verreck, (BPRC, the Netherlands)
10.00 – 10.15 Kevin Urdahl, (SC, United States)
10.15 – 10.30 Simon Clarke, (PHE, United Kingdom)

10.30 – 11.00 **Coffee break**

**Innovation in vaccine technologies and modelling**

11.00 – 11.15 "The Impact of STriTuVaD computational platform on TB vaccine pipeline: improvements and future implications" - Francesco Pappalardo, (UniCt, Italy)
11.15 – 11.30 Robin Mogg, (GMRI, United States)
11.30 – 11.45 Chathika Weerasuriya, (LSHTM, United Kingdom)
11.45 – 12.00 "Human Multi-Organ-Chip-based disease modelling: progress and challenges" - Reyk Horland, (TissUse, Germany)

12.00 – 13.00 **Lunch (restaurant Eurotel)**
Wednesday 29 January 2020 afternoon
(Maison des Congrès)

13.15 – 15.15 Current and future global TB vaccine R&D to maintain and diversify the pipeline
(Plenary chair: Hannu Laang, GTBVP)

13.15 – 13.30 TBVAC2020 final results, (Danielle Roordink, TBVI, the Netherlands)
13.30 – 13.45 NIH IMPAc-TB projects, (Rhea Coler, IDRI; Kevin Urdahl, SC, United States)
13.45 – 14.00 Update on GMRI activities, (Alex Schmidt, GMRI, United States)
14.00 – 14.15 CTVD discovery roadmap, (Anne Kasmar, BMGF, United States)
14.15 – 14.30 European TB vaccine priorities for Horizon Europe, (Hannu Laang, EC, Belgium)
14.30 – 14.45 Opportunities for vertical and horizontal collaboration, (Dereck Tait, IAVI, South Africa; Ole Olesen, EVI, Germany)
14.45 – 15.00 Overall conclusions (session chair)

15.00 – 15.15 Closure
(Nick Drager, TBVI, the Netherlands)

15.15 – 16.00 Coffee available in the foyer of the Eurotel

15.30 – 19.00 Side meetings

15.30 – 17.20 Progress in EDCTP-funded clinical development (room Diablerets) (Only for invited guests)

15.30 – 16.30 R&I group meeting to discuss conclusion from conference (Room Isenau) (Only for R&I members or invited guests)

17.00 – 19.00 GTBVP meeting – (room Villar) (Only for GTBVP members and on invitation)

17.30 – 19.00 P&CDT meeting – (room Diablerets) (Only for P&CDT members)

19.00 Dinner (restaurant Eurotel)
Eurotel Victoria
Les Diablerets
Fam. Stéphane et Alexandra Wartner
Chemin du Vernex
1865 Les Diablerets
Switzerland
Phone: +41 24 492 37 21

Accommodation should be arranged via registration on website TBVI

Contact person TBVI:
Cora Agterdenbosch,
TBVI
Runderweg 6
8219 PK Lelystad
The Netherlands
Phone: +31 320 277550
e-mail: cora.agterdenbosch@tbvi.eu

Transportation:
Trains from/to Geneva Airport, change at Aigle.
120 minutes, schedules on http://www.sbb.ch